Erasca Inc (ERAS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.50B
Last updated: Nov 17, 2026 at 11:05 AM ET
Erasca Inc (ERAS) Stock Forecast
Analysts expect Erasca (ERAS) to earn -$0.98 per share in the fiscal year ending Dec 31, 2026. Of 9 analysts, 7 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 6 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 78% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 22.2% |
| Buy | 5 | 55.6% |
| Hold | 2 | 22.2% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.98
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.64
- EPS consensus
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.98 | -$1.06 to -$0.86 | 8 |
| Dec 31, 2027 | -$0.64 | -$0.80 to -$0.34 | 8 |
Quarterly Estimates
The EPS consensus is -$0.14 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.14 | -$0.17 to -$0.07 | 12 |
| Mar 31, 2027 | -$0.14 | -$0.17 to -$0.08 | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 7 upward and 14 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 6 |
| Fiscal year ending Dec 31, 2027 | 2 | 7 |
| Quarter ending Mar 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.97.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.98 | -$0.98 | -$0.98 | -$0.98 | -$0.97 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.64 | -$0.62 | -$0.62 | -$0.62 | -$0.58 | N/A |
| Quarter ending Mar 31, 2027 | -$0.14 | -$0.13 | -$0.13 | -$0.13 | -$0.12 | N/A |
Frequently Asked Questions About ERAS
What is the ERAS stock forecast?
Consensus analyst estimates put Erasca's EPS at -$0.98 for the fiscal year ending Dec 31, 2026. The consensus rating from 9 analysts is Buy.
How do analysts rate ERAS stock?
Of 9 analysts covering Erasca, 2 rate it Strong Buy, 5 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ERAS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.98, with estimates from -$1.06 to -$0.86 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.64, with estimates from -$0.80 to -$0.34 from 8 analysts.
How many analysts cover ERAS?
9 analysts rate Erasca stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ERAS pages: Overview, Earnings, Forecast, Financials, Competitors